Navigation Links
Michael J. Fox Foundation Awards $2.1 Million to Drive Six Industry Teams' Pre-Clinical Development of Neuroprotective Parkinson's Therapies

NEW YORK, Jan. 19 /PRNewswire-USNewswire/ -- As part of its mission to speed development of transformative treatments for Parkinson's disease, The Michael J. Fox Foundation for Parkinson's Research announced a total of $2.1 million in awards to six biotech and pharmaceutical companies under its industry-exclusive Therapeutics Development Initiative (TDI). The funding will drive pre-clinical projects pushing forward investigations of promising neuroprotective therapeutic targets for Parkinson's.

Three teams will focus on strategies to address inflammation and oxidative stress, while two will investigate ways to target the Parkinson's-implicated protein alpha-synuclein (including FoldRx Pharmaceuticals' continuing investigation of small-molecule drug candidates to inhibit alpha-synuclein toxicity, funded by MJFF since 2007). The remaining team will investigate HDACs, a family of enzymes that have been shown to enhance expression of potential protective factors in preclinical models of PD and may also regulate clearance of toxic proteins.

While MJFF welcomes applications from industry researchers under all of its programs, TDI -- first launched in 2006 -- is the Foundation's only industry-exclusive funding stream. It is a key element of MJFF's strategy to 'de-risk' preclinical PD research for biotech and pharmaceutical companies, thus expanding industry investment in Parkinson's therapeutic development and helping push the most promising research to the next stage.

Projects selected for funding are listed below. Detailed information, including grant abstracts and researcher bios, is available in the Searchable Database of Funded Grants at As with all MJFF grants, full funding is contingent on the achievement of predetermined, specific milestones and on researchers' agreement to make the results of their work available to the Parkinson's research community.

Projects Focused on Inflammation and Oxidative Stress

Design of Neuroprotective Drugs to Reduce Oxidative Damage and Alpha-Synuclein Toxicity in Parkinson's Disease

Stig Hansen, Ph.D., Carmot Therapeutics, Inc.

Targeting TLR2 as a Novel Therapy for Parkinson's Disease

Andrew Parker, Ph.D., Opsona Therapeutics LTD

An Innovative Drug for Disease-Modifying Treatment of Parkinson's Disease

Philipp Wabnitz, Ph.D., InterMed Discovery GmbH

Projects Focused on Alpha-Synuclein

Determination and Validation of the Molecular Target of J3, a Neuroprotective Lead Compound, for Its Optimization as a Disease-modifying Candidate for Parkinson's Disease

Christine Bulawa, Ph.D., FoldRx Pharmaceuticals, Inc.

Developing Autophagy Enhancers as Disease-modifying Therapeutics for Parkinson's Disease

John Dunlop, Ph.D., Pfizer Global Research and Development


Potential Efficacy of a Novel, Orally Bioavailable, CNS-penetrant HDAC Inhibitor in Pre-clinical Models of Parkinson's Disease

Holger Patzke, Ph.D., Envivo Pharmaceuticals

TDI is launched bi-annually with applications accepted each spring and fall. It has been enthusiastically received by industry researchers. To date the Foundation has awarded $18.6 million total for 39 industry-led projects under the initiative.

About The Michael J. Fox Foundation

The Michael J. Fox Foundation is dedicated to finding a cure for Parkinson's disease through an aggressively funded research agenda and to ensuring the development of improved therapies for those living with Parkinson's today. To date, the Foundation has funded almost $170 million in research. For more information on TDI and the Foundation's industry strategy, please visit

SOURCE Michael J. Fox Foundation



SOURCE Michael J. Fox Foundation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. D-M-S Holdings, Inc. Announces the Filing of a Lawsuit Against Veridian Healthcare, LLC, Steven M. Bisulca and Michael Mazza
2. Kendle Appoints J. Michael Sprafka, MPH, PhD, Vice President, Kendle Consulting
3. Takeda San Francisco, Inc. Appoints Michael Buckley, Ph.D. Vice President of Process Sciences
4. Sigma-Aldrich(R) Receives Award From Michael J. Fox Foundation to Develop Parkinsons Disease Research Models
5. Michael J. Fox Foundation-Funded Team Pursuing Glutamate-Based Treatment for Parkinsons Disease Hits Major Milestone
6. Michael J. Fox Foundation Commits Up to $12 Million for Targeted Parkinsons Therapeutic Development in 2010
7. Lilly and New York City Mayor Michael R. Bloomberg Announce Lilly Agrees to be First Tenant of East River Science Park; Issue Urgent Call for Healthcare Reform that Protects Innovation and Jobs
8. Michael J. Fox Foundation Awards Over $2 Million for Validation of 10 Parkinsons Therapeutic Targets
9. Michael J. Fox Foundation Commits up to $6.5 Million in Funding for Critical Challenges in Parkinsons Disease
10. Michael J. Fox Foundation Awards $2.1 Million to Improve Drug Delivery in Parkinsons Disease
11. Michael J. Fox Foundation Awards $2.9 Million for Two New Parkinsons Disease Clinical Trials
Post Your Comments:
(Date:6/23/2016)... WAYNE, Pa. , June 23, 2016 ... provider, will launch its next generation clinical outcomes platform, Bracket ... DIA Meeting held on June 26 – 30, 2016 in ... 6.0, the first electronic Clinical Outcome Assessment product of its ... DIA Booth #715. Bracket eCOA 6.0 is a ...
(Date:6/23/2016)... Ill. and INDIANAPOLIS , ... students receiving a Lilly Diabetes Tomorrow,s Leaders Scholarship is ... 2016 scholarship winners, announced today online at ... let type 1 diabetes stand in the way of ... has supported the Foundation,s scholarship program since 2012, and ...
(Date:6/23/2016)... June 23, 2016 Revolutionary technology ... Oticon , industry leaders in advanced audiology and ... Oticon Opn ™, the world,s first internet connected ... for IoT devices.      (Photo: ... a number of ,world firsts,: , TwinLink™ ...
Breaking Medicine Technology:
(Date:6/25/2016)... , ... June 25, 2016 , ... Conventional wisdom preaches ... success. In terms of the latter, setting the bar too high can result in ... than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... ... , ... Those who have experienced traumatic events may suffer from a complex ... as drug or alcohol abuse, as a coping mechanism. To avoid this pain and ... a traumatic event. , Trauma sufferers tend to feel a range of emotions, from ...
(Date:6/24/2016)... ... ... was in a crisis. Her son James, eight, was out of control. Prone to extreme ... “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there was ... other children and say he was going to kill them. If we were driving ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Global law ... magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition are ... , Seven Greenberg Traurig Shareholders received special honors as members of this year’s Legal ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Comfort Keepers® ... American Cancer Society and the Road To Recovery® program to drive cancer patients to ... and other adults to ensure the highest quality of life and ongoing independence. ...
Breaking Medicine News(10 mins):